NAMPT and cancer: Compared to traditional small-molecule NAMPT inhibitors, antibody–drug conjugates (ADCs) can selectively target cancer cells through antibodies binding to cancer-specific cell surface markers, thereby sparing normal cells from systemic NAD depletion.